FOLH1 and posterior cortical atrophy: The development of PSMA-targeting peptidomimetics has already remarkably advanced the diagnostics and therapy of PCa, specifically highlighted by the theranostic agent PSMA-617 (approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2022 as a last-line therapeutic for metastatic castration-resistant PCa (mCRPC)) [8,9].